8-苯基薄荷醇 | 134256-18-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: 8-苯基薄荷醇
• 英文名称: 5-methyl-2-(1-methyl-1-phenyl-ethyl)-cyclohexanol
• 英文别名: 5-methyl-2-(2-phenylpropan-2-yl)cyclohexan-1-ol
• CAS: 134256-18-1
• 化学式: C₁₆H₂₄O
• mdl: MFCD20144583
• 分子量: 232.366
• InChiKey: WTQIZFCJMGWUGZ-UHFFFAOYSA-N

物化性质

• 沸点：
  333.1±11.0 °C(Predicted)
• 密度：
  0.986±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.625
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  8-苯基薄荷醇 在 sulfur 作用下， 以 氘代氯仿 为溶剂， 生成
  参考文献：
  名称：

  Determination of the absolute configuration of chiral cyclic alcohols using diamine derivatizing agents by 31P NMR spectroscopy

  摘要：

  The absolute configuration and enantiomeric excess of chiral cyclic alcohols can be predicted from the P-31 NMR spectra of the two diastereoisomers obtained with organophosphorus diamino-derivatizing agents (CDAs) and the chiral secondary I alcohol, according to a simplified model taking into account the spatial location of the substituents of the chiral alcohol center and the P NMR signals of the two diastereoisomers. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetasy.2006.07.042
• 作为产物：
  描述：

  N-氯代丁二酰亚胺 、 薄荷脑 、 methyl(phenyl)(o-tolyl)phosphine 以Using 8-phenylmenthol as the chiral alcohol in the oxidation of PAMP, gave PAMPO in 53% ee的产率得到8-苯基薄荷醇
  参考文献：
  名称：

  Chiral phosphorus compounds

  摘要：

  一种立体选择性制备P-手性四配位磷化合物的过程，该过程包括在电子亲和物的存在下，将从手性醇，手性胺或手性硫醇组成的第一反应物与包含P-手性三配位磷化合物的第二反应物反应。

  公开号：

  US08471067B2

文献信息

• EPOTHILONE DERIVATIVES, METHOD FOR PRODUCING SAME AND THEIR PHARMACEUTICAL USE
  申请人：——

  公开号：US20030144523A1

  公开（公告）日：2003-07-31

  This invention relates to the new epothilone derivatives of general formula I, 1 in which substituents Y, Z R 2a , R 2b , R 3 , R 4a , R 4b , D—E, R 5 , R 6 , R 7 , R 8 and X have the meanings that are indicated in more detail in the description. The new compounds interact with tubulin by stabilizing microtubuli that are formed. They are able to influence the cell-splitting in a phase-specific manner and are suitable for treating malignant tumors, for example, ovarian, stomach, colon, adeno-, breast, lung, head and neck carcinomas, malignant melanomas, acute lymphocytic and myelocytic leukemia. In addition, they are suitable for anti-angiogenesis therapy as well as for treatment of chronic inflammatory diseases (psoriasis, arthritis). To avoid uncontrolled proliferation of cells and for better compatibility of medical implants, they can be applied or introduced into polymer materials. The compounds according to the invention can be used alone or to achieve additive or synergistic actions in combination with other principles and classes of substances that can be used in tumor therapy.

  本发明涉及具有通式I的新埃波替隆衍生物，其中取代基Y、Z、R2a、R2b、R3、R4a、R4b、D—E、R5、R6、R7、R8和X的含义在描述中更详细地指出。这些新化合物通过与微管蛋白的相互作用来稳定形成的微管。它们能够以阶段特异性的方式影响细胞分裂，并适用于治疗恶性肿瘤，例如卵巢、胃、结肠、腺体、乳腺、肺、头颈癌、恶性黑色素瘤、急性淋巴细胞和骨髓细胞白血病。此外，它们还适用于抗血管生成治疗以及治疗慢性炎性疾病（银屑病、关节炎）。为了避免细胞的不受控制的增殖以及提高医疗植入物的相容性，它们可以应用于或引入到聚合物材料中。根据发明的化合物可以单独使用，也可以与其他可用于肿瘤治疗的原理和物质类别结合使用，以实现相加或协同作用。
• Novel epothilone derivatives, method for the preparation thereof and their pharmaceutical use
  申请人：——

  公开号：US20040058969A1

  公开（公告）日：2004-03-25

  The invention relates to novel epothilone derivatives of general formula (1), wherein R 5 represents a halogen atom or a cyano group and the other substituents have the meanings as cited in the description. The novel compounds interact with tubulin by stabilizing formed microtubules. They are capable of influencing the cell division in a phase-specific manner and are well-suited for the treatment of malignant tumors, for example, ovarian, stomach, colon, adeno, breast, lung, head and neck carcinomas, malignant melanoma, acute lymphocytic and myelocytic leukemia. In addition, they are well-suited for anti-angiogenesis therapy and for the treatment of chronic inflammable medical disorders (psoriasis, arthritis). In order to prevent uncontrolled cell growths as well as to improve the compatibility of medical implants, the inventive epothilone derivatives can be applied to or introduced into polymeric materials. The inventive compounds can be used alone or in order to obtain additive or synergistic effects, in conjunction with additional principles and substance classes that can be used in tumor therapy. 1

  本发明涉及一类通式（1）的新埃博霉素衍生物，其中R 5 代表卤素原子或氰基，其他取代基的含义如描述中引用。这些新颖化合物通过与微管蛋白作用稳定形成的微管。它们能够以特定阶段的方式影响细胞分裂，非常适合治疗恶性肿瘤，例如卵巢癌、胃癌、结肠癌、腺癌、乳腺癌、肺癌、头颈癌、恶性黑色素瘤、急性淋巴细胞和骨髓细胞白血病。此外，它们还非常适合用于抗血管生成治疗和慢性炎症性医疗疾病（银屑病、关节炎）的治疗。为了防止不受控制的细胞生长以及提高医疗植入物的相容性，本发明的埃博霉素衍生物可以施加或引入到聚合物材料中。本发明的化合物可以单独使用，或者为了获得添加剂或协同效应，与肿瘤治疗中可用的其他原理和物质类别联合使用。 1
• DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS
  申请人：Brotherton-Pleiss Christine E.

  公开号：US20100160388A1

  公开（公告）日：2010-06-24

  Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.

  公式I的化合物：或其药用可接受的盐，其中m、n、R1、R2、R3、R4和R5按本文件定义。还公开了制造这些化合物的方法以及使用这些化合物治疗与P2X7嘌呤能受体相关疾病的方法。
• DIHYDROPYRIDONE AMIDES AS P2X7 MODULATORS
  申请人：Lopez-Tapia Francisco Javier

  公开号：US20100160387A1

  公开（公告）日：2010-06-24

  Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with the P2X7 purinergic receptor.

  式I的化合物： 或其药用可接受的盐，其中m、n、R1、R2、R3、R4和R5如本文所定义。还公开了制备这些化合物的方法，并将这些化合物用于治疗与P2X7嘌呤受体相关的疾病。
• [EN] NOVEL SYNTHETIC OPTIONS TOWARDS THE MANUFACTURE OF (6R,10S)-10- {4-[5-CHLORO-2-(4-CHLORO-1H-1,2,3-TRIAZOL-1-YL)PHENYL]-6-OXO-1(6H)- PYRIMIDINYL}- 1-(DIFLUOROMETHYL)-6-METHYL-1,4,7,8,9,10-HEXAHYDRO-11,15 -(METHENO)PYRAZOLO [4,3-B] [1,7] DIAZACYCLOTETRADECIN-5(6H)-ONE<br/>[FR] NOUVELLES OPTIONS SYNTHÉTIQUES POUR LA FABRICATION DE (6R,10S)-10-{4-[5-CHLORO-2-(4-CHLORO-1H-1,2,3-TRIAZOL-1-YL) PHÉNYL]-6-OXO-1(6H)-PYRIMIDINYL}1-(DIFLUOROMÉTHYL)-6-MÉTHYL-1,4,7,8,9,10-HEXAHYDRO-11,15- (METHENO)PYRAZOLO [4,3-B] [1,7] DIAZACYCLOTÉTRADECIN-5 (6H)-ONE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2020210613A1

  公开（公告）日：2020-10-15

  Highly efficient methods are provided for preparing key intermediates in the synthesis of Compound (I), which are broadly applicable and can provide selected components having a variety of substituents groups.

  为合成化合物（I）的关键中间体提供了高效的方法，这些方法具有广泛的适用性，并且可以提供具有各种取代基团的选定组分。